Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies
October 30, 2025
SITC Spring in Tucson, AZ
March 31, 2026
Q1 ended on a strong note, with Graeme Wald (CEO) and Gouri Betigeri (Head of Business Development) spending four days in Lisbon with the Austrade delegation, representing the company.
Lisbon provided an ideal setting for meaningful engagement across biotech, pharma, and the broader R&D ecosystem. Discussions spanned the full development spectrum—from early discovery through to clinical strategy and commercialisation—reflecting the increasingly global nature of innovation in our sector.
Across meetings with biotech companies, pharmaceutical partners, investors, and service providers, a consistent theme emerged: the importance of focused collaboration to accelerate development and improve patient outcomes.
These interactions have strengthened existing relationships and created new opportunities, reinforcing our commitment to building globally relevant partnerships in support of next-generation oncology innovation.
